4//SEC Filing
Taylor Michael Douglas 4
Accession 0001209191-21-025551
CIK 0001654151other
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 6:00 AM ET
Size
13.7 KB
Accession
0001209191-21-025551
Insider Transaction Report
Form 4
Taylor Michael Douglas
DirectorSee Remarks
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2021-04-01−8,000→ 2,354 totalExercise: $1.89Exp: 2025-12-17→ Common Stock (8,000 underlying) - Sale
Common Stock
2021-04-01$45.69/sh−4,994$228,169→ 906 total - Exercise/Conversion
Common Stock
2021-04-01$1.89/sh+8,000$15,120→ 8,000 total - Sale
Common Stock
2021-04-01$44.80/sh−2,100$94,074→ 5,900 total - Sale
Common Stock
2021-04-01$46.72/sh−906$42,328→ 0 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated August 24, 2020 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.32 to $45.27, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.32 to $46.29, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.42 to $46.95, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of March 1, 2014, subject to continued service through such dates.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
Related Parties
1- filerCIK 0001494875
Filing Metadata
- Form type
- 4
- Filed
- Apr 5, 8:00 PM ET
- Accepted
- Apr 6, 6:00 AM ET
- Size
- 13.7 KB